• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Inverness closes Standard Diagnostics buyout

UPDATE: Inverness closes Standard Diagnostics buyout

February 1, 2010 By MassDevice staff

Inverness Medical Innovations Inc. (NYSE:IMA) is hitting the acquisitions trail hard in 2010.

The Waltham, Mass.-based diagnostics and lab equipment maker closed its deal to buy a three-quarters stake in Korean rapid diagnostics maker Standard Diagnostics (KDQ:066930) for up to $216.6 million.

Inverness bid about $35.72 per share for 75.79 percent or just more than 6 million shares of Standard Diagnostics, provided that at least roughly 2.4 million shares, or 30 percent of the total issued, were tendered.

Inverness said roughly 4.8 million shares were tendered by SD shareholders, representing about 62 percent of the company.

SD president and CEO Young Shik Cho (who’s also the company’s largest shareholder) tendered his 720,000-share stake in the firm as part of the deal. Now that the minimum tender mark has been reached, Inverness and Cho together own more than half of the company.

The $35.72 per share offer is a 33 percent premium over SD’s 90-day trailing average of about $26.67. SD shares closed at about $33.39 Feb. 1. The bid is slated for settlement Feb. 8.

The run at Standard Diagnostics, which makes reagents and devices aimed at detecting hepatitis, infectious diseases, tumors, fertility and drugs, is the latest buyout bid for Inverness. The company inked a group of distribution-to-acquisition deals with Epocal Inc. last week that could lead to it paying $255 million for the of Ottawa, Canada-based blood testing equipment maker. That five-year arrangement starts with a deal for Inverness to sell Epocal’s Epoc rapid blood gas and electrolyte analysis platform. Inverness paid $20 million for the right to distribute the system worldwide, except for Japan, India, Bangladesh, Nepal, Bhutan and Sri Lanka; a second agreement calls for the two companies to collaborate in expanding Inverness’ portfolio of point-of-care testing platforms. The third and perhaps biggest deal will see Inverness pay a base price of up to $172.5 million to buy Epocal outright, contingent on that company achieving certain gross margin and financial milestones before Oct. 31, 2014. Epocal can add another $82.5 million to the purchase price if it meets other benchmarks, including product development and gross margin goals.

Inverness also bought British CRO Mologic in October, registering nearly 129,000 shares worth about $5 million held by a group of Mologic founders and managers.

IMA put some black in back on the ledger during the third quarter. The company logged a 22.1 percent increase in revenues compared with Q3 2008, largely on a jump in sales of its influenza diagnostic tests and contributions from acquisitions.

Inverness posted net income of $14.3 million on net sales of $535.8 million for the three months ended Sept. 30, compared with a net loss of $9.1 million on sales of $438.8 million during the same period last year. The company credited strong sales of products related to Swine Flu for the improvement.

Filed Under: Business/Financial News, Diagnostics, Mergers & Acquisitions, News Well Tagged With: Alere, Inverness Medical Innovations Inc.

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy